2,3-二甲基-4-乙氧基吡啶氮氧化物 | 1034065-92-3

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 2,3-二甲基-4-乙氧基吡啶氮氧化物
• 英文名称: 4-ethoxy-2,3-dimethylpyridine N-oxide
• 英文别名: 2,3-dimethyl-4-ethoxypyridine N-oxide；4-ethoxy-2,3-dimethylpyridine-1-oxide；4-ethoxy-2,3-dimethyl-1-oxidopyridin-1-ium
• CAS: 1034065-92-3
• 化学式: C₉H₁₃NO₂
• 分子量: 167.208
• InChiKey: PJNWFOFDMHWRFO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  34.7
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2,3-二甲基-4-乙氧基吡啶氮氧化物 在 氯化亚砜 、 三氟乙酸酐 作用下， 以 二氯甲烷 为溶剂， 反应 53.5h， 生成 5-fluoro-2-(((3-methyl-4-ethoxypyridin-2-yl)methyl)thio)-1H-benzo[d]imidazole
  参考文献：
  名称：

  [EN] ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS
  [FR] LIGANDS DU RÉCEPTEUR D'ARYL-HYDROCARBONÉ ET LEURS ANALOGUES POUR LA PRÉVENTION ET LE TRAITEMENT DE TROUBLES INFLAMMATOIRES

  摘要：

  芳香烃受体（AHR）激动剂及其在治疗、预防或降低与减少芳香烃受体（AHR）表达减少相关的炎症性疾病风险方面的用途，包括坏死性肠炎，用于预防、降低与减轻与减少芳香烃受体（AHR）表达减少相关的炎症性疾病的严重程度，并作为婴儿营养配方中的添加剂。

  公开号：

  WO2022061140A1
• 作为产物：
  描述：

  2,3-二甲基吡啶 在 硫酸 、 硝酸 、 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 30.0h， 生成 2,3-二甲基-4-乙氧基吡啶氮氧化物
  参考文献：
  名称：

  [EN] ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS
  [FR] LIGANDS DU RÉCEPTEUR D'ARYL-HYDROCARBONÉ ET LEURS ANALOGUES POUR LA PRÉVENTION ET LE TRAITEMENT DE TROUBLES INFLAMMATOIRES

  摘要：

  芳香烃受体（AHR）激动剂及其在治疗、预防或降低与减少芳香烃受体（AHR）表达减少相关的炎症性疾病风险方面的用途，包括坏死性肠炎，用于预防、降低与减轻与减少芳香烃受体（AHR）表达减少相关的炎症性疾病的严重程度，并作为婴儿营养配方中的添加剂。

  公开号：

  WO2022061140A1

文献信息

• Helicobacter pylori eradicating agent having inhibitory activity on gastric acid secretion
  申请人：Ito Masaharu

  公开号：US08778975B2

  公开（公告）日：2014-07-15

  Disclosed are: a compound which is stable in an acid, has an antibacterial effect against a bacterium Helicobacter pylori, can exert a satisfactory level of an antibacterial effect when used singly, does not affect an enteric bacterium, has an antibacterial effect against a bacterium resistant to an antibacterial agent, and has an inhibitory effect on gastric acid secretion; and a pharmaceutical composition comprising the compound. Specifically disclosed are: a compound represented by the general formula (I) or a salt thereof; and a pharmaceutical composition comprising the compound or the salt thereof: wherein R represents a linear alkyl group having 4 to 8 carbon atoms, preferably 5 to 7 carbon atoms.

  本发明涉及一种在酸性条件下稳定，对幽门螺杆菌具有抗菌作用，单独使用时能够发挥满意的抗菌作用，不影响肠道细菌，对抗抗菌剂抗性菌株具有抗菌作用，并且对胃酸分泌具有抑制作用的化合物；以及包含该化合物的制药组合物。具体揭示了一种由通式（I）表示的化合物或其盐；以及包含该化合物或其盐的制药组合物：其中R表示具有4至8个碳原子的线性烷基，优选5至7个碳原子。
• Structure-Activity Relationship of Omeprazole and Analogs as Helicobacter pylori Urease Inhibitors
  作者：Thomas C. Kuehler、Jan Fryklund、Nils-ke Bergman、Jessica Weilitz、Adrian Lee、Haakan Larsson

  DOI：10.1021/jm00025a008

  日期：1995.12

  Helicobacter pylori urease belongs to a family of highly conserved urea-hydrolyzing enzymes. A common feature of these enzymes is the presence of two Lewis acid nickel ions and a reactive cysteine residue in the active site. The H+/K(+)-ATPase inhibitor omeprazole is a prodrug of a sulfenamide which covalently modifies cysteine residues on the luminal side of the H+/K(+)-ATPase of gastric parietal cells. Omeprazole and eight analogues were selected based on their chemical, electronic, and kinetic properties, and each was incubated with viable H. pylori in phosphate-buffered saline at pH 7.4 for 30 min, after which 100 mM urea was added and the amount of ammonia formed analyzed after a further 10 min. Inhibition between 0% and 100% at a 0.1 mM concentration was observed for the different analogues and could be expressed as a function of the pKa-value of the pyridine, the pKa-value of the benzimidazole, the overall lipophilicity, and, most importantly, the rate of sulfenamide formation, in a quantitative structure-activity relationship. The inhibition was potentiated by a lower pH (favoring the formation of the sulfenamide) but abolished in the presence of beta-mercaptoethanol (a scavenger of the sulfenamide). Structural analogues incapable of yielding the sulfenamide did not inhibit ammonia production. Treatment of Helicobacter felis-infected mice with 230 mumol/kg flurofamide b.i.d. for 4 weeks, known to potently inhibit urease activity in vivo, as a means of eradicating the infection, was tested and compared with the effect of 125 mumol/kg omeprazole b.i.d. for 4 weeks. Neither treatment proved efficacious.
• HELICOBACTER PYLORI ERADICATING AGENT HAVING INHIBITORY ACTIVITY ON GASTRIC ACID SECRETION
  申请人：Arigen Pharmaceuticals, Inc.

  公开号：EP2103608B1

  公开（公告）日：2012-08-29
• US8778975B2
  申请人：——

  公开号：US8778975B2

  公开（公告）日：2014-07-15
• [EN] ARYL HYDROCARBON RECEPTOR LIGANDS AND THEIR ANALOGUES FOR THE PREVENTION AND TREATMENT OF INFLAMMATORY DISORDERS<br/>[FR] LIGANDS DU RÉCEPTEUR D'ARYL-HYDROCARBONÉ ET LEURS ANALOGUES POUR LA PRÉVENTION ET LE TRAITEMENT DE TROUBLES INFLAMMATOIRES
  申请人：UNIV JOHNS HOPKINS

  公开号：WO2022061140A1

  公开（公告）日：2022-03-24

  Aryl hydrocarbon receptor (AHR) agonists and their use in treating or preventing or reducing the risk of an inflammatory disorder associated with a reduced expression of an aryl hydrocarbon receptor (AHR), including necrotizing enterocolitis, for preventing, reducing the risk of, or reducing the severity of an inflammatory disorder associated with a reduced expression of an aryl hydrocarbon receptor (AHR), and as an additive to infant nutritional formulas.

  芳香烃受体（AHR）激动剂及其在治疗、预防或降低与减少芳香烃受体（AHR）表达减少相关的炎症性疾病风险方面的用途，包括坏死性肠炎，用于预防、降低与减轻与减少芳香烃受体（AHR）表达减少相关的炎症性疾病的严重程度，并作为婴儿营养配方中的添加剂。